CoChat

Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway

Open access
Iida, Keitaro, Naiki, Taku, Naiki‐Ito, Aya, Suzuki, Shugo, Kato, Hiroyuki, Nozaki, Satoshi, Nagai, Takashi, Etani, Toshiki, Nagayasu, Yuko, Ando, Ryosuke, Kawai, Noriyasu, Yasui, Takahiro, Takahashi, Satoru · 2020 · Cancer Science
Cited by 91

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Luteolin is a natural flavonoid with strong anti–oxidative properties that is reported to have an anti–cancer effect in several malignancies other than bladder cancer. In this study, we describe the effect of luteolin on a human bladder cancer cell line, T24, in the context of the regulation of p21, thioredoxin‐1 (TRX1) and the mechanistic target of rapamycin (mTOR) pathway. Luteolin inhibited cell survival and induced G2/M cell‐cycle arrest, p21 upregulation and downregulation of phospho(p)‐S6, which is downstream of mTOR signaling. Luteolin also upregulated TRX1 and reduced intracellular reactive oxygen species production. In a subcutaneous xenograft mouse model using the rat bladder cancer cell line, BC31, tumor volumes were significantly decreased in mice orally administered luteolin compared to control. Immunohistochemical analysis revealed that increased p21 and decreased p‐S6 expression were induced in the luteolin treatment group. Moreover, in another in vivo N‐butyl‐N‐(4‐hydroxybutyl) nitrosamine (BBN)‐induced rat bladder cancer model, the oral administration of luteolin led to a trend of decreased bladder tumor dimension and significantly decreased the Ki67‐labeling index and p‐S6 expression. Furthermore, the major findings on the metabolism of luteolin suggest that both plasma and urine luteolin‐3ʹ‐O‐glucuronide concentrations are strongly associated with the inhibition of cell proliferation and mTOR signaling. Moreover, a significant decrease in the squamous differentiation of bladder cancer is attributed to plasma luteolin‐3ʹ‐glucuronide concentration. In conclusion, luteolin, and in particular its metabolized product, may represent another natural product‐derived therapeutic agent that acts against bladder cancer by upregulating p21 and inhibiting mTOR signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.14334

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 91

Metadata

Authors
Iida, K., Naiki, T., Naiki‐Ito, A., Suzuki, S., Kato, H., Nozaki, S., Nagai, T., Etani, T., Nagayasu, Y., Ando, R., Kawai, N., Yasui, T., & Takahashi, S.
Venue
Cancer Science
Publisher
Wiley
Published
2020-02-24
Volume
111
Issue
4
Pages
1165-1179
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W3003597907
Cited by
91
References
7
FWCI
6.21
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway. https://app.cochat.ai/papers/10.1111/cas.14334
The paper
Iida, K., Naiki, T., Naiki‐Ito, A., Suzuki, S., Kato, H., Nozaki, S., Nagai, T., Etani, T., Nagayasu, Y., Ando, R., Kawai, N., Yasui, T., & Takahashi, S. (2020). Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway. Cancer Science. https://doi.org/10.1111/cas.14334

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.